A new license to adapt EORTC questionnaires into electronic versions
As of 15 May 2021, the EORTC will introduce a [...]
Surviving glioblastoma? EORTC Brain Tumour Group explores the factors that contribute to long-term survival
GLIOBLASTOMAS represent almost 50% of malignant primary brain tumors in [...]
European Stakeholder Group Statement – Maintaining the exchange of critical health data
We welcome the draft adequacy decision on the UK data [...]
Long-term results from MINDACT trial confirm importance of gene expression signature in choosing breast cancer patients who can be spared chemotherapy GalleryLong-term results from MINDACT trial confirm importance of gene expression signature in choosing breast cancer patients who can be spared chemotherapy
Long-term results from MINDACT trial confirm importance of gene expression signature in choosing breast cancer patients who can be spared chemotherapy
The decision on whether or not to give chemotherapy after [...]
New statement to replace the FDA 1572 form for non-IND trials supported by NCI
Collaboration between research groups is essential for sharing expertise and [...]
PRESS RELEASE: Generating recommendations for the design, analysis and interpretation of patient- reported outcome (PRO) data for cancer clinical trials: the launch of SISAQOL-IMI GalleryPRESS RELEASE: Generating recommendations for the design, analysis and interpretation of patient- reported outcome (PRO) data for cancer clinical trials: the launch of SISAQOL-IMI
PRESS RELEASE: Generating recommendations for the design, analysis and interpretation of patient- reported outcome (PRO) data for cancer clinical trials: the launch of SISAQOL-IMI
An international multidisciplinary consortium, co-led by the European Organisation for [...]
When will the EU take treatment optimisation seriously?
New, innovative treatments for disease are being brought to market [...]
EORTC embarked on a membership renewal programme
In 2020, EORTC embarked on an ambitious membership renewal programme, [...]
Interview of EORTC members about COVID-19 impact on cancer clinical trials
The COVID-19 pandemic has affected cancer clinical trials in many [...]
PRESS RELEASE: EORTC 1945 OligoRARE trial in oligometastatic rare cancers receives support by Anticancer Fund & Rising Tide Foundation
Brussels, February 2, 2021 – EORTC 1945 OligoRARE trial in [...]
